This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Abrams, J. A. Search for Related Content Social Bookmarking                   What's this?

Review: Chemoprevention of esophageal adenocarcinoma

Division of Digestive and Liver Diseases, Columbia University Medical Center New York, NY, USA, ja660{at}columbia.edu

The incidence of esophageal adenocarcinoma (EAC) is rising rapidly in Western countries, and effective chemoprevention for this malignancy is lacking. Endoscopic surveillance of patients with Barrett's esophagus is currently employed to diagnose EAC at earlier stages, but this strategy has several limitations. Non-steroidal anti-inflammatory drugs and proton pump inhibitors are the most promising agents for prevention of EAC, and a randomized controlled trial of aspirin and esomeprazole is ongoing. Other agents under investigation include green tea, berries, and antioxidants. Cost-effectiveness analyses have shown that chemopreventive agents need to be highly effective at preventing EAC in order to have benefit beyond endoscopic surveillance.

Key Words: esophageal cancer • adenocarcinoma • chemoprevention

Therapeutic Advances in Gastroenterology, Vol. 1, No. 1, 7-18 (2008)
DOI: 10.1177/1756283X08093568


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?